Lung Cancer: Symptoms, Diagnosis, Staging & NHS Treatment

Lung cancer is the third most common cancer in the UK and the leading cause of cancer death, responsible for approximately 35,000 deaths each year in England — more than breast and bowel cancer combined. Around 48,000 new cases are diagnosed annually in the UK. The five-year survival rate, at approximately 16%, remains lower than many comparable cancers, largely because the majority of cases are diagnosed at an advanced stage when curative treatment is no longer possible. However, this picture is rapidly changing: NHS England’s targeted lung health checks, new surgical techniques, and a revolution in systemic treatment with immunotherapy and targeted therapies mean that outcomes are improving faster for lung cancer than almost any other cancer. Early diagnosis is everything — survival at stage I exceeds 80%, compared with under 5% at stage IV. This guide explains the types of lung cancer, warning symptoms, NHS diagnosis pathways, and current treatment options.

Types of Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

NSCLC accounts for approximately 85% of all lung cancers and includes three main subtypes:

  • Adenocarcinoma: the most common subtype (around 40% of NSCLC); arises from mucus-secreting cells; increasingly common in non-smokers and women; typically found in the outer lung tissue; strongly associated with EGFR, ALK, and other targetable driver mutations
  • Squamous cell carcinoma: closely linked to smoking; arises from the cells lining the large airways (bronchi); typically central in location
  • Large cell carcinoma: a catch-all category for NSCLC not fitting the above; tends to grow and spread quickly

Small Cell Lung Cancer (SCLC)

SCLC accounts for around 15% of lung cancers. It grows and spreads very rapidly — often metastasising before symptoms appear — and is almost exclusively associated with smoking. Although it initially responds well to chemotherapy and radiotherapy, it has a high recurrence rate and overall prognosis is poor. SCLC is staged as “limited” (confined to one side of the chest) or “extensive” (spread beyond).

Mesothelioma

Mesothelioma is a separate malignancy of the pleura (the lining of the lung), almost entirely caused by asbestos exposure. The UK has one of the highest mesothelioma rates in the world, reflecting past industrial asbestos use in shipbuilding, construction, and manufacturing. It typically presents 20–50 years after asbestos exposure. It is not strictly a lung cancer but is managed by thoracic oncology teams and shares many features with lung cancer presentation.

Symptoms of Lung Cancer

Lung cancer is often asymptomatic in early stages, which is why most cases are diagnosed late. When symptoms do occur, they include:

  • Persistent cough — lasting 3 or more weeks, or a change in a chronic cough
  • Haemoptysis — coughing up blood, even a small amount; this requires urgent investigation
  • Breathlessness — new or worsening shortness of breath
  • Chest pain — persistent pain in the chest, shoulder, or back
  • Unexplained weight loss and fatigue
  • Hoarseness — caused by tumour pressing on the recurrent laryngeal nerve
  • Recurrent chest infections — the same area of lung repeatedly affected suggests obstruction
  • Finger clubbing — bulging of fingertips; a non-specific but important paraneoplastic sign
  • Superior vena cava obstruction (SVCO): swelling of the face, neck, and arms with venous distension; a medical emergency caused by tumour compressing the SVC

Many of these symptoms — particularly cough and breathlessness — are common and overlap with COPD and other respiratory conditions, especially in smokers. This overlap contributes to diagnostic delay. Anyone with haemoptysis should be referred urgently regardless of other factors.

Risk Factors

  • Smoking: responsible for approximately 72% of lung cancer cases in the UK; risk increases with pack-years smoked and reduces (though does not normalise) after quitting
  • Radon gas: a naturally occurring radioactive gas; the second leading cause of lung cancer in the UK, responsible for approximately 1,100 deaths per year. High radon areas include Cornwall, Devon, Somerset, Northamptonshire, and parts of Scotland. Homes can be tested and mitigation is possible.
  • Occupational exposures: asbestos, silica, diesel fumes, arsenic, chromium, nickel; industrial workers may be eligible for IIDB claims
  • Air pollution: IARC classifies outdoor air pollution (including fine particulate matter PM2.5) as a Group 1 carcinogen for lung cancer
  • Family history: first-degree relatives of lung cancer patients have a 2-fold elevated risk
  • Never-smokers: approximately 15% of UK lung cancers occur in never-smokers, disproportionately women; EGFR-mutated adenocarcinoma is particularly common in this group

NHS Diagnosis Pathway

NICE NG12 specifies the referral criteria for suspected lung cancer. GPs should refer urgently under the 2-week wait pathway for:

  • Chest X-ray findings suggesting lung cancer (at any age)
  • Haemoptysis in adults aged 40+ who are current or ex-smokers
  • Any of the following in adults 40+ with unexplained symptoms: cough, fatigue, breathlessness, chest pain, weight loss, or appetite loss (if two or more symptoms present, or any alongside smoking history)

The diagnostic pathway typically involves:

  • Chest X-ray: first-line imaging; can miss small or early tumours
  • CT scan of chest and upper abdomen: detailed staging of the primary tumour and lymph nodes
  • PET-CT scan: whole-body scan to detect distant metastases; standard before surgical or radical treatment planning
  • Bronchoscopy: flexible camera through the airways to take biopsies of central tumours
  • CT-guided percutaneous biopsy: for peripheral tumours not accessible by bronchoscopy
  • EBUS (endobronchial ultrasound): bronchoscopy with ultrasound guidance to sample mediastinal lymph nodes; increasingly standard at specialist centres
  • Brain MRI: for staging in NSCLC being considered for radical treatment
  • Molecular/genomic testing: all NSCLC should be tested for EGFR, ALK, ROS1, KRAS G12C, BRAF, MET, RET, NTRK, and PD-L1 expression — these determine eligibility for targeted therapies and immunotherapy

NHS Treatment Options

Surgery

Surgery offers the best chance of cure for early-stage (I–IIB) NSCLC in patients fit enough to undergo resection. Options include lobectomy (removal of a lobe), segmentectomy, or pneumonectomy (whole lung removal), typically performed by video-assisted thoracoscopic surgery (VATS) or robotic surgery at specialist thoracic centres. Pre-operative lung function testing (spirometry, DLCO, shuttle walk test) assesses fitness for resection. NICE recommends that all patients being considered for surgery are discussed at a specialist lung cancer multidisciplinary team (MDT) meeting.

Radiotherapy

Stereotactic ablative radiotherapy (SABR) — also called SBRT — delivers high-dose, precisely targeted radiotherapy in 3–8 fractions. NICE has approved SABR as an alternative to surgery for stage I NSCLC in patients who are medically inoperable or who decline surgery, with outcomes comparable to surgery for small tumours. SABR is available at specialist NHS centres.

Radical radiotherapy (conventionally fractionated, over 4–7 weeks) combined with concurrent chemotherapy is used for stage III NSCLC not amenable to surgery. Durvalumab (Imfinzi) — an anti-PD-L1 checkpoint inhibitor — is given as consolidation therapy after chemoradiotherapy for stage III NSCLC and has significantly improved progression-free survival; it is NICE-approved and available on the NHS.

Targeted Therapies

The landscape of NSCLC treatment has been transformed by targeted agents against oncogenic driver mutations. NICE has approved multiple agents available on the NHS Cancer Drugs Fund:

  • EGFR inhibitors: osimertinib (Tagrisso) is the preferred first-line option for EGFR-mutated advanced NSCLC; it crosses the blood-brain barrier and significantly improves overall survival
  • ALK inhibitors: alectinib (Alecensa), brigatinib (Alunbrig), and lorlatinib (Lorbrena) for ALK-rearranged NSCLC
  • KRAS G12C inhibitors: sotorasib (Lumakras) — NICE approved for previously treated KRAS G12C-mutated NSCLC, historically an “undruggable” target
  • RET, MET, ROS1, NTRK inhibitors: several agents approved for rarer driver mutations

Immunotherapy

For NSCLC without driver mutations, anti-PD-1/PD-L1 checkpoint inhibitors have transformed outcomes. NICE-approved options include:

  • Pembrolizumab (Keytruda): first-line monotherapy for high PD-L1 expressors (TPS ≥50%), or in combination with chemotherapy for all-comers regardless of PD-L1 expression
  • Nivolumab + ipilimumab: dual checkpoint blockade for first-line treatment of metastatic NSCLC with high tumour mutational burden
  • Atezolizumab (Tecentriq): adjuvant therapy after surgery for resected EGFR/ALK-negative NSCLC with PD-L1 ≥1%

Chemotherapy

Platinum-based chemotherapy (cisplatin or carboplatin with pemetrexed, gemcitabine, or paclitaxel) remains a cornerstone of treatment for advanced NSCLC without targetable mutations, and as first-line combination with immunotherapy. For SCLC, platinum-etoposide chemotherapy is standard, with atezolizumab added for extensive-stage disease.

NHS Targeted Lung Health Checks

NHS England has been rolling out Targeted Lung Health Checks (TLHCs) — a low-dose CT (LDCT) screening programme for current and ex-smokers aged 55–74. Evidence from the UK NELSON and US NLST trials demonstrated that LDCT screening reduces lung cancer mortality by 20–26% in high-risk populations. The programme invites eligible individuals from GP registers in participating areas for a risk assessment, then LDCT for those above a risk threshold. By 2029, NHS England aims to have TLHC available nationwide. This is the most significant development in lung cancer early detection in a generation — people in eligible age groups and smoking history should check whether their local area offers TLHCs via their GP or NHS website.

UK Support Organisations

  • Roy Castle Lung Cancer Foundation (roycastle.org) — the UK’s leading lung cancer charity; helpline, patient information, clinical trials database
  • Lung Cancer UK (lungcanceruk.org) — patient support, nurse helpline, peer support groups
  • Macmillan Cancer Support (macmillan.org.uk) — practical and emotional support; helpline 0808 808 0000
  • Mesothelioma UK (mesothelioma.uk.com) — specialist support for mesothelioma patients and families; legal and benefits advice
  • Cancer Research UK (cancerresearchuk.org) — clinical trials database and comprehensive information

What Competitors Miss About Lung Cancer

1. Radon gas is the second biggest cause of lung cancer in the UK — and most people have never heard of it. Approximately 1,100 lung cancer deaths per year in the UK are attributable to radon — a radioactive gas released naturally from granite and certain soils that can accumulate in buildings. In high-radon areas (Cornwall, Devon, Somerset, parts of Scotland and the Midlands), indoor radon levels can be elevated enough to pose significant cancer risk, and the cumulative risk to a smoker living in a high-radon home is substantially amplified. The UK Health Security Agency provides free radon maps and radon test kits can be ordered online. This is actionable, potentially lifesaving information that is almost entirely absent from standard online health guides about lung cancer.

2. Lung cancer in never-smokers is a distinct disease — with different biology and better treatment options. Up to 15% of UK lung cancers occur in people who have never smoked, and these are disproportionately adenocarcinomas with targetable driver mutations (EGFR, ALK, ROS1). A never-smoker diagnosed with lung cancer should expect comprehensive molecular profiling — they are much more likely to have a targetable mutation and to benefit from oral targeted therapies (like osimertinib) rather than chemotherapy. GPs and patients sometimes assume that absence of a smoking history makes lung cancer less likely and delay investigation; in fact, any new persistent respiratory symptom in a never-smoker deserves the same urgent attention as in a smoker.

3. The NHS Targeted Lung Health Check is among the most important NHS cancer programmes — but uptake is being hampered by stigma. Lung cancer has a unique stigma problem: because it is so strongly associated with smoking, patients (and sometimes healthcare professionals) can feel an implicit attribution of blame. This stigma reduces screening uptake — some eligible smokers and ex-smokers avoid TLHCs because they feel they “deserve” their risk. Studies consistently show lung cancer patients report higher levels of blame, shame, and less social support than patients with other cancers. Removing stigma from lung cancer — which affects non-smokers too, and in which prior smoking is never a reason to withhold treatment — is a public health priority that patient advocacy organisations like Roy Castle Lung Cancer Foundation are actively addressing.

4. Molecular testing is mandatory but not always happening. NICE and NHS England guidelines specify that all newly diagnosed advanced NSCLC should receive full molecular profiling including EGFR, ALK, ROS1, KRAS G12C, BRAF, MET, RET, NTRK, and PD-L1 — because treatment selection depends entirely on these results. However, tissue adequacy, turnaround times, and variation between trusts means not all patients receive comprehensive profiling in a timely manner. Liquid biopsy (circulating tumour DNA from a blood test) is increasingly available as a rapid alternative or complement where tissue is insufficient. Patients with advanced NSCLC should ask their oncologist explicitly whether full molecular profiling has been completed and which mutations were tested.

Related Health Guides on YourHealthXpert

If you found this guide helpful, explore these related topics: